225 related articles for article (PubMed ID: 27194514)
1. Failure of combination therapy for Staphylococcus aureus bone infection: a case of in vivo selection with resistance to rifampicin and fusidic acid.
Aubin GG; Bémer P; Guillouzouic A; Launay E; Geffroy L; Touchais S; Corvec S
Infect Dis (Lond); 2016 Sep; 48(9):699-702. PubMed ID: 27194514
[TBL] [Abstract][Full Text] [Related]
2. Mutations in rpoB and fusA cause resistance to rifampicin and fusidic acid in methicillin-resistant Staphylococcus aureus strains from a tertiary hospital in Malaysia.
Lim KT; Teh CS; Yusof MY; Thong KL
Trans R Soc Trop Med Hyg; 2014 Feb; 108(2):112-8. PubMed ID: 24336696
[TBL] [Abstract][Full Text] [Related]
3. Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus.
Howden BP; Grayson ML
Clin Infect Dis; 2006 Feb; 42(3):394-400. PubMed ID: 16392088
[TBL] [Abstract][Full Text] [Related]
4. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus.
O'Neill AJ; Cove JH; Chopra I
J Antimicrob Chemother; 2001 May; 47(5):647-50. PubMed ID: 11328777
[TBL] [Abstract][Full Text] [Related]
5. Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus.
Wang JL; Tang HJ; Hsieh PH; Chiu FY; Chen YH; Chang MC; Huang CT; Liu CP; Lau YJ; Hwang KP; Ko WC; Wang CT; Liu CY; Liu CL; Hsueh PR
Int J Antimicrob Agents; 2012 Aug; 40(2):103-7. PubMed ID: 22612900
[TBL] [Abstract][Full Text] [Related]
6. Genomic analysis reveals different mechanisms of fusidic acid resistance in Staphylococcus aureus from Danish atopic dermatitis patients.
Edslev SM; Clausen ML; Agner T; Stegger M; Andersen PS
J Antimicrob Chemother; 2018 Apr; 73(4):856-861. PubMed ID: 29253168
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of antibiotic resistance to orally administrable antibiotics in staphylococcal bone and joint infections in one of the largest university hospitals in Germany: is there a role for fusidic acid?
Klein S; Nurjadi D; Eigenbrod T; Bode KA
Int J Antimicrob Agents; 2016 Feb; 47(2):155-7. PubMed ID: 26774158
[TBL] [Abstract][Full Text] [Related]
8. Community-acquired methicillin-resistant Staphylococcus aureus in bone and joint infections: development of rifampicin resistance.
Donaldson AD; Chan RC; Gosbell IB
Med J Aust; 2006 Feb; 184(4):196. PubMed ID: 16489910
[No Abstract] [Full Text] [Related]
9. Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus.
Lannergård J; Norström T; Hughes D
Antimicrob Agents Chemother; 2009 May; 53(5):2059-65. PubMed ID: 19289529
[TBL] [Abstract][Full Text] [Related]
10. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections.
Saginur R; Stdenis M; Ferris W; Aaron SD; Chan F; Lee C; Ramotar K
Antimicrob Agents Chemother; 2006 Jan; 50(1):55-61. PubMed ID: 16377667
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of Staphylococcus aureus to fusidic acid: Canadian data.
Rennie RP
J Cutan Med Surg; 2006; 10(6):277-80. PubMed ID: 17241597
[TBL] [Abstract][Full Text] [Related]
12. Activity of Fusidic Acid Tested against Staphylococci Isolated from Patients in U.S. Medical Centers in 2014.
Farrell DJ; Mendes RE; Castanheira M; Jones RN
Antimicrob Agents Chemother; 2016 Jun; 60(6):3827-31. PubMed ID: 27021326
[TBL] [Abstract][Full Text] [Related]
13. A fusidic acid-resistant epidemic strain of Staphylococcus aureus carries the fusB determinant, whereas fusA mutations are prevalent in other resistant isolates.
O'Neill AJ; Larsen AR; Henriksen AS; Chopra I
Antimicrob Agents Chemother; 2004 Sep; 48(9):3594-7. PubMed ID: 15328136
[TBL] [Abstract][Full Text] [Related]
14. Dissemination of fusidic acid resistance among Staphylococcus aureus clinical isolates.
Yu F; Liu Y; Lu C; Lv J; Qi X; Ding Y; Li D; Huang X; Hu L; Wang L
BMC Microbiol; 2015 Oct; 15():210. PubMed ID: 26463589
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of disseminated methicillin-resistant Staphylococcus aureus with fosfomycin, cefoperazone/sulbactam and rifampin followed by fusidic acid and rifampin.
Apisarnthanarak A; Mundy LM
Int J Infect Dis; 2007 May; 11(3):283-4. PubMed ID: 16876452
[No Abstract] [Full Text] [Related]
16. Characterization of fusidic acid-resistant Staphylococcus aureus isolates in the community of Casablanca (Morocco).
Elazhari M; Abu-Quatouseh LF; Elhabchi D; Zerouali K; Dersi N; Saile R; Timinouni M; Becker K
Int J Med Microbiol; 2012 Mar; 302(2):96-100. PubMed ID: 22197537
[TBL] [Abstract][Full Text] [Related]
17. Staphylococcus aureus resistant to fusidic acid among Swedish children: a follow-up study.
Osterlund A; Kahlmeter G; Haeggman S; Olsson-Liljequist B;
Scand J Infect Dis; 2006; 38(5):334-4. PubMed ID: 16724423
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections, with focus on doxycycline.
Hamad T; Hellmark B; Nilsdotter-Augustinsson Å; Söderquist B
APMIS; 2015 Dec; 123(12):1055-60. PubMed ID: 26547372
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of fusidic acid resistance in Staphylococcus aureus.
Besier S; Ludwig A; Brade V; Wichelhaus TA
Mol Microbiol; 2003 Jan; 47(2):463-9. PubMed ID: 12519196
[TBL] [Abstract][Full Text] [Related]
20. High usage of topical fusidic acid and rapid clonal expansion of fusidic acid-resistant Staphylococcus aureus: a cautionary tale.
Williamson DA; Monecke S; Heffernan H; Ritchie SR; Roberts SA; Upton A; Thomas MG; Fraser JD
Clin Infect Dis; 2014 Nov; 59(10):1451-4. PubMed ID: 25139961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
